Masitinib Mesylate
Highly Selective Tyrosine Kinase Inhibitor for Advanced Veterinary Oncology & Immunology
Masitinib Mesylate (CAS 790299-79-5) is a cutting-edge veterinary active pharmaceutical ingredient developed under strict in-house quality standards to ensure exceptional purity and stability. As a highly selective tyrosine kinase inhibitor (TKI) , it has become a cornerstone therapy in veterinary oncology and immunology, particularly for cell mast tumors and chronic inflammatory disorders in companion animals.
Chemical & Physical Characteristics
| CAS Number | 790299-79-5 |
| Molecular Formula | C₂₈H₃₀N₆OS |
| Molar Mass | 498.64 g/mol |
| Melting Point | 90–95 °C |
| Solubility | DMSO: Highly soluble | Water: <1 mg/mL | Ethanol: 4 mg/mL |
| Appearance | Off-white to pale beige powder |
| Storage | Refrigerated storage recommended |
Structural & Pharmacological Profile
Masitinib Mesylate is a benzamide derivative belonging to chemical classes such as N-alkylpiperazines, 1,3-thiazoles, and pyridines. It functions by selectively inhibiting key tyrosine kinases-most notably the stem cell factor (SCF) receptor c-Kit .
▸ Suppresses tumor cell proliferation
▸ Reduces mast cell activation and degranulation
▸ Modulates immune and inflammatory signaling
Veterinary Applications
1. Mast Cell Tumors (MCTs)
▸ Limits tumor growth and improves survival time
▸ Suitable as monotherapy or in combination with surgery or chemotherapy
2. Chronic Inflammatory Disorders
▸ Atopic dermatitis
▸ Asthma
▸ Irritable bowel syndrome (IBS)
▸ Immune-mediated inflammatory diseases
3. Emerging Oncology Applications
▸ Melanoma
▸ Osteosarcoma
▸ Other c-Kit–positive malignancies
Key Advantages
- Highly selective mechanism for improved safety
- Convenient oral administration
- Generally well tolerated with manageable side effects
- Dual application in oncology and immunology
Why Masitinib Mesylate Is Transformative in Veterinary Medicine
The shift toward targeted therapies has revolutionized veterinary care. Masitinib Mesylate stands out for its precision in blocking cancer-driving pathways while preserving healthy tissue. Its expanding research base and dual role in oncology and chronic inflammatory disease management position it as a future-focused therapeutic solution for companion animals.
FAQs
Q: Where is your factory located?
▸ Zhumadian City, Henan Province, China.
Q: When was your factory established?
▸ 2019.
Q: What are your main export markets?
▸ Europe, South America, the Middle East, and Asia.
Conclusion
Masitinib Mesylate (CAS 790299-79-5) is an advanced veterinary API delivering targeted and reliable therapeutic performance in mast cell tumors, inflammatory diseases, and emerging oncology indications. Its selective kinase inhibition and expanding clinical potential make it an essential component of modern veterinary treatment strategies.
Hot Tags: api masitinib mesylate for veterinary cas 790299-79-5, China api masitinib mesylate for veterinary cas 790299-79-5 manufacturers, suppliers, factory, Dexmedetomidine Hydrochloride for Veterinary CAS 145108 58 3, Imidacloprid CAS 138261 41 3, compounds for veterinary drug screening, veterinary small molecule formulations for drug screening, Dexmedetomidine Hydrochloride, Masitinib for veterinary
